This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting
by Zacks Equity Research
AstraZeneca (AZN) drug Faslodex receives FDA approval for a label extension for Faslodex in the first-line monotherapy setting for the treatment of advanced breast cancer.
Here's Why Clovis Stock Is Up Almost 60% So Far in 2017
by Zacks Equity Research
Clovis Oncology (CLVS) stock is on the rise. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
Pfizer's Ibrance in First-Line Combo Breast Cancer Study
by Zacks Equity Research
Pfizer, Inc. (PFE) and six international cancer research groups are collaborating on a combination study to explore the use of Ibrance for first-line treatment of advanced breast cancer.
Immunomedics' Progress in Phase II Cancer Study Encouraging
by Zacks Equity Research
Immunomedics, Inc. (IMMU) announced encouraging interim results from a phase II study on its cancer candidate, labetuzumab govitecan. Shares were up 7% on Monday in response.
Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning
by Zacks Equity Research
Pfizer, Inc.'s (PFE) leukemia candidate, Besponsa received FDA approval, though with a boxed warning on the label.
The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk
Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo
by Arpita Dutt
Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President's manufacturing council and data on Bristol-Myers' (BMY) Opdivo.
Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
by Zacks Equity Research
Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.
Top Analyst Reports for Pfizer, TJX Companies & Honda
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), TJX Companies (TJX) and Honda (HMC).
Catalyst (CPRX) Focused on Development of Pipeline Candidates
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) focuses on the development of its pipeline candidates Firdapse and CPP-115.
Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses
by Zacks Equity Research
Clovis Oncology (CLVS) reported significant increase in Rubraca sales in the second quarter. Moreover, the company is focused on expanding Rubraca's label in second-line ovarian cancer.
Horizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View
by Zacks Equity Research
Horizon Pharma plc (HZNP) topped both earnings and sales estimate in second-quarter 2017 and raised its sales guidance for 2017.
The Zacks Analyst Blog Highlights: Apple, Pfizer, Intel, Chevron and Exxon Mobil
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Pfizer, Intel, Chevron and Exxon Mobil
Q2 Earnings Fail to Impress Pharma ETF
by Sweta Killa
The string of earnings beat failed to boost pharma ETFs.
Dow 30 Stock Roundup: Apple Impresses, Pfizer Beats on Earnings
by Swarup Gupta
The Dow breached the psychological 22,000 barrier during a week of strong gains.
Market News For August 04, 2017
by Zacks Equity Research
The blue-chip index registered its 33rd record for 2017 to finish above the 22,000 threshold yet again on a day marked by losses for other benchmarks.
Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals
by Arpita Dutt
Pfizer's (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.
Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat
by Zacks Equity Research
Momenta Pharmaceuticals Inc (MNTA)'s loss per share came in line with estimates in the second quarter of 2017 while sales beat estimates driven by Glatopa 20mg.
Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Aerie Pharmaceuticals, Inc.'s (AERI) narrower-than-expected loss in the second quarter was encouraging.
Company News For August 02, 2017
by Zacks Equity Research
Companies in the news are: XRX,ADM,RCL,PFE
Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings?
by Zacks Equity Research
DENTSPLY Sirona's (XRAY) results are likely to be boosted by surging dental & healthcare consumables space in the yet-to-be-reported second quarter.
Q2 Earnings From UA, PFE And ADM
by Zacks Equity Research
Q2 Earnings From UA, PFE And ADM
Pfizer (PFE) Surpasses Q2 Earnings Estimates, Misses Sales
by Zacks Equity Research
Pfizer, Inc. (PFE) beat expectations for earnings while missing the same for sales in Q2. It raised the lower end of its 2017 adjusted earnings guidance but kept the revenue expectations intact.
Q2 Earnings Tuesday: Mixed Bag for Most
by Mark Vickery
UnderArmour (UAA), Pfizer (PFE), Archer Daniels Midland (ADM), among others, hit the tape this morning.